Attovia Therapeutics, Inc.
Research Attovia Therapeutics, Inc. (ATTO) on Bullrun: market cap USD 634.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATTO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 634.10M
- Financial periodQ2 2026
- RevenueUSD 450.00K
- Net income-USD 20.69M
- Free cash flow-USD 16.86M
Valuation Snapshot
latest market cap is USD 634.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.35M | -USD 60.63M | -USD 61.51M | n/a | -2.37 | USD 40.19M | USD 5.26M | -USD 107.44M |
| FY2024 | USD 0 | -USD 39.80M | -USD 36.81M | n/a | -1.75 | USD 30.63M | USD 0 | -USD 46.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-19 | USD 634.10M | n/a | n/a | n/a |
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Attovia Therapeutics, Inc.'s market cap?
Attovia Therapeutics, Inc.'s market capitalization is USD 634.10M.
What does Attovia Therapeutics, Inc. do?
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.